Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

Abstract

This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression ( p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.

Downregulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis

“…It is also interesting to note that fH or a related protein is a marker for bladder cancer, suggesting a link between C resistance and escape from immune surveillance (28). CD55 has been identifi ed as a tumor-associated antigen and a high expression level of CD55 in colorectal cancer tissue is correlated with a signifi cant decrease in survival (29). Also, lower CD46 has been found to be inversely related with high levels of C3 deposited in renal and cervical cancer tissue (30).…”

Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal Cancer

“…Increased expression of CRPs has been described in several different malignancies, including colorectal (14), gastric (15), lung (16), renal (17), and breast (18) cancers. Specifically, increased DAF expression has been observed in 75% of colorectal cancers compared with matched normal tissue (19), and increased DAF expression has been associated with poor prognosis in patients with colorectal cancer (14).…”

“…Increased expression of CRPs has been described in several different malignancies, including colorectal (14), gastric (15), lung (16), renal (17), and breast (18) cancers. Specifically, increased DAF expression has been observed in 75% of colorectal cancers compared with matched normal tissue (19), and increased DAF expression has been associated with poor prognosis in patients with colorectal cancer (14). In addition to the angiogenic growth factors such as vascular endothelial growth factor and basic fibroblast growth factor (20), DAF expression is regulated by proinflammatory mediators such as lipopolysaccharide (21), tumor necrosis factor-␣ (22), and IL-1␤ (23).…”

Comparison of the expression of complement regulatory proteins CD46, CD55 and CD59 in primary colon cancer and synchronous/metachronous liver metastases

“…As Durrant et al stated, a high expression of CD55 correlated negatively with the outcome in patients with primary colorectal cancer tumors [14]. In a group of 136 patients, the correlation of CD55 expression in tumor biopsies and 7-year survival of patients was assessed.…”